IRIDEX Corporation — FY 2011 Form 10-K
Reporting period: Fiscal year ended December 31, 2011 (52 weeks); the filing is an annual report, not a standalone Q4 report. Comparative results are recast to present ophthalmology as continuing operations and aesthetics as discontinued operations. The aesthetics sale to Cutera closed in February 2012 for approximately $5.1 million.
Business context and financial performance
IRIDEX develops and sells ophthalmic laser systems, delivery devices, consumables, and related services. U.S. sales are primarily direct; international sales use approximately 70 distributors across more than 100 countries. Recurring revenue includes consumables and service.
| Metric | FY 2011 | FY 2010 |
|---|---|---|
| Continuing revenue | $33.2 million | $32.3 million |
| Gross profit / gross margin | $16.3 million / 49.1% | $16.2 million / 50.1% |
| Operating income | $1.9 million | $1.2 million |
| Continuing net income | $2.1 million | $1.7 million |
| Total net income, including discontinued operations | $2.6 million | $3.0 million |
| Diluted EPS, continuing operations | $0.21 | $0.16 |
| Cash from continuing operating activities | $2.3 million | $1.1 million |
Liquidity, debt, and material changes
- Year-end cash and cash equivalents were $10.8 million, versus $8.3 million a year earlier; working capital was $20.6 million, versus $17.2 million. Management stated that cash and expected operating cash flows were sufficient for the next 12 months.
- The company reported no debt outstanding. It had a secured revolving facility of up to $5.0 million, subject to borrowing-base conditions, with maturity on June 11, 2012; no funds had been requested or made available under the agreement as of year-end. The company reported compliance with covenants.
- Revenue from continuing operations increased 2.8%. Domestic system revenue rose 16.1%; international system revenue rose 1.1%; recurring revenue was flat at $16.2 million; OEM revenue fell 28.6% to $0.5 million.
- Gross margin declined one percentage point, mainly because of a greater mix of lower-margin systems. Continuing operating income improved, including a $1.274 million net benefit shown as a reduction of operating expenses for legal settlement activity.
- Reported total net income fell from $3.0 million to $2.6 million, primarily alongside lower income from discontinued aesthetics operations. Aesthetics revenue was $10.8 million in 2011 versus $11.4 million in 2010.
- Operating leases totaled $2.4 million in remaining minimum payments. Capital expenditures were $0.2 million. No off-balance-sheet arrangements were reported.
Outlook, commentary, and risks
- Management described the aesthetics divestiture as enabling focus on ophthalmology, but warned that the sale removes a business that covered its direct costs. The company said it would need to adjust costs and/or grow ophthalmology revenue to remain profitable. No numeric revenue or earnings guidance was provided.
- Management cited recovery in capital spending and renewed physician interest in laser photocoagulation as support for system sales. Consumables faced strong competition and customer price sensitivity; OEM sales were expected to keep declining as the related product reached end of life.
- In November 2011, Alcon agreed to pay $1.5 million in connection with a license and distribution agreement for IRIDEX’s GreenTip cannulas. The company recorded the payment as part of ongoing operating activity. It also reported $0.8 million of Synergetics settlement income in each of 2011 and 2010 and expected a further $0.8 million payment in April 2012.
- Key risks include the post-divestiture cost and revenue transition; reliance on international distributors and sales; intense competition, including pharmaceutical alternatives; reimbursement and healthcare policy changes; product-development and regulatory uncertainty; dependence on sole- or limited-source suppliers; and potential product liability, recalls, or quality-system enforcement.
- Other notable items: a $0.3 million increase in the estimated RetinaLabs earn-out liability was recorded in Q4 2011; the year-end earn-out liability was $0.765 million. The company repurchased $0.648 million of stock in 2011 and announced an increase of its repurchase authorization to $4 million through May 2013. A full $11.7 million valuation allowance remained against deferred tax assets.
Most important facts for investors to verify
- Post-sale ophthalmology revenue, recurring consumables and service trends, and whether the reduced cost base can sustain profitability.
- Cash generation and working-capital use, particularly the rise in inventory to $6.7 million from $5.6 million, and the timing and terms of the $5.1 million sale proceeds.
- Collection and accounting treatment of the expected $0.8 million Synergetics payment, and the final amount and timing of contingent earn-out payments.
- Renewal, replacement, or repayment status of the revolving credit facility, whose stated maturity was June 11, 2012.
- Progress on new products and clinical/regulatory clearances, distributor performance, and any effects of competition or reimbursement changes.